Impact of psychostimulants on vesicular monoamine transporter function

European Journal of Pharmacology

Volumn 479, Issue 1-3, 2003, Pages 283-289

  Fleckenstein, Annette E ^a   Hanson, Glen R ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Amphetamine; Cocaine; Methylphenidate; Vesicular monoamine transporter

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMFONELIC ACID; AMPHETAMINE DERIVATIVE; CARRIER PROTEIN; DIZOCILPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; ETICLOPRIDE; FLUOXETINE; LOBELINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PSYCHOSTIMULANT AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

DEGENERATIVE DISEASE; DOPAMINE UPTAKE; INHIBITION KINETICS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 0242721911     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.08.077     Document Type: Article

References (54)

1. Anderson B.B., Chen G., Gutman D.A., Ewing A.G. Dopamine levels of two classes of vesicles are differentially depleted by amphetamine. Brain Res. 788:1998;294-301.
2. Brown J.M., Hanson G.R., Fleckenstein A.E. Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74:2000;2221-2223.
3. Brown J.M., Hanson G.R., Fleckenstein A.E. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J. Pharmacol. Exp. Ther. 298:2001;1150-1153.
4. Brown J.M., Riddle E.L., Sandoval V., Weston R.K., Hanson J.E., Crosby M.J., Ugarte Y.V., Gibb J.W., Hanson G.R., Fleckenstein A.E. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J. Pharmacol. Exp. Ther. 302:2002;497-501.
5. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIIwain K.L., Orrison B., Chen A., Ellis C.E., Palor R., Lu B., Nussbaum R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22:2002;8797-8807.
6. Crosby M.J., Hanson J.E., Fleckenstein A.E., Hanson G.R. Phencyclidine increases vesicular dopamine uptake. Eur. J. Pharmacol. 438:2002;75-78.
7. Dwoskin L.P., Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63:2002;89-98.
8. Erickson J.D., Eiden L.E., Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10993-10997.
9. Fischer J.F., Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208:1979;203-209.
10. Fleckenstein A.E., Gibb J.W., Hanson G.R. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406:2000;1-13.
11. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., Kuhl D.E. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40:1996;873-884.
12. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19:1999;2424-2431.
13. German D.C., Liang C.L., Manaye K.F., Lane K., Sonsalla P.K. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience. 101:2000;1063-1069.
14. Gibb J.W., Kogan F.J. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn-Schmiedeberg's Arch. Pharmacol. 310:1979;185-187.
15. Gonzalez A.M., Walther D., Pazos A., Uhl G.R. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res. Mol. Brain Res. 22:1994;219-226.
16. Graham D.G., Tiffany S.M., Bell W.R. Jr., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14:1978;644-653.
17. Hansen J.P., Riddle E.L., Sandoval V., Brown J.M., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J. Pharmacol. Exp. Ther. 300:2002;1093-1100.
18. Harvey D.C., Lacan G., Melegan W.P. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Exp. Brain Res. 133:2000;349-358.
19. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64:1995;919-924.
20. Hogan K.A., Staal R.G., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 74:2000;2217-2220.
21. Hotchkiss A., Gibb J.W. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase in rat brain. J. Pharmacol. Exp. Ther. 214:1980;257-262.
22. Hotchkiss A., Morgan M.E., Gibb J.W. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxlase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci. 25:1979;1373-1378.
23. Johnson R.G. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68:1988;232-307.
24. Johnson-Davis K.L., Truong J.G., Fleckenstein A.E., Wilkins D.G. The role of VMAT2 in the induction of tolerance to the neurotoxic effects of methamphetamine. Abstr.-Soc. Neurosci. Abstr. 962.8:2003.
25. Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18:1998;1979-1986.
26. Larsen K.E., Fon E.A., Hastings T.G., Edwards R.H., Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22:2002;8951-8960.
27. Lehericy S., Brandel J.P., Hirsch E.C., Anglade P., Villares J., Scherman D., Duyckaerts C., Javoy-Agid F., Agid Y. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res. 659:1994;1-9.
28. Liang N.Y., Rutledge C.O. Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem. Pharmacol. 31:1982;2479-2484.
29. Little K.Y., Krolewski D.M., Zhang L., Cassin B.J. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am. J. Psychiatry. 160:2003;47-55.
30. Marek G.J., Vosmer G., Seiden L.S. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 513:1990;274-279.
31. Nirenberg M.J., Liu Y., Peter D., Edwards R.H., Pickel V.M. The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc. Natl. Acad. Sci. U. S. A. 92:1995;8773-8777.
32. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
33. Raiteri M., Cerrito F., Cervoni A.M., Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208:1979;195-202.
34. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235:1982;93-103.
35. Riddle E.L., Topham M.K., Haycock J.W., Hanson G.R., Fleckenstein A.E. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449:2002;71-74.
36. Riddle, E.L., Hanson, G.R., Fleckenstein, A.E., (in press). Amphetamine and methylphenidate differentially and selectively traffic the vesicular monoamine transporter-2. Abstr.-Soc. Neurosci.
37. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22:2002;8705-8710.
38. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304:2003;1181-1187.
39. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233:1985;539-544.
40. Schmitz Y., Lee C.J., Schmauss C., Gonon F., Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects of D2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21:2001;5916-5924.
41. Speciale S.G., Liang C.L., Sonsalla P.K., Edwards R.H., German D.C. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience. 84:1998;1177-1185.
42. Staley J.K., Talbot J.Z., Ciliax B.J., Miller G.W., Levey A.I., Kung M.P., Kung H.F., Mash D.C. Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Res. 747:1997;219-229.
43. Sulzer D., Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron. 5:1990;797-808.
44. Sulzer D., Maidment N.T., Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60:1993;527-535.
45. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:1995;4102-4108.
46. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., Uhl G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U. S. A. 94:1997;9938-9943.
47. Teng L., Crooks P.A., Dwoskin L.P. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with D-amphetamine. J. Neurochem. 71:1998;258-265.
48. Thibaut F., Faucheux B.A., Marquez J., Villares J., Menard J.F., Agid Y., Hirsch E.C. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res. 692:1995;233-243.
49. Truong J.G., Horton D.J., Hanson G.R., Fleckenstein A.E. Quinpirole increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. Abstr.-Soc. Neurosci. Abstr. 373.12:2003.
50. Wagner G.C., Ricaurte G.W., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181:1980;151-160.
51. Wagner G.C., Lucot J.B., Schuster C.R., Seiden L.S. Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res. 270:1983;285-288.
52. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2:1996;699-703.
53. Wilson J.M., Levey A.I., Bergeron C., Kalasinsky K., Ang L., Peretti F., Adams V.I., Smialek J., Anderson W.R., Shannak K., Deck J., Niznik H.B., Kish S.J. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40:1996;428-439.
54. Woolverton W.L., Ricaurte G.A., Forno L., Seiden L.S. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486:1989;73-78.